RESUMO
BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a new ribonucleic acid (RNA) beta-coronavirus, responsible for a worldwide pandemic. Very few cases of SARS-COV-2-related emphysema have been described, except among patients with chronic obstructive pulmonary disease. The thoracic CT scan is the key examination for the diagnosis and allows to evaluate the severity of the pulmonary involvement. The prognosis of the patient with giant emphysema (GE) on coronavirus disease 2019 (COVID-19) in critical or severe form remains poor. We report an original case of COVID-19 pneumonia, critical form, complicated by a giant compressive left emphysema of 22.4 cm in a young subject without respiratory comorbidities. CASE PRESENTATION: A 34-year-old man was hospitalized for left laterothoracic pain. He had no prior medical history. The physical examination revealed tympany on percussion of the left lung. The CT scan confirmed COVID-19 pneumonia with 95% lung involvement. Also, the presence of a voluminous left sub pleural emphysema of 22.4 cm with compression of the ipsilateral pulmonary parenchyma as well as the mediastinal structures towards the right side. The diagnosis COVID-19 pneumonia, critical form, complicated by a compressive left giant emphysema was made. He was put on oxygen, a dual antibiotic therapy, a corticotherapy, and curative doses of enoxaparin. A thoracic drainage surgery was performed at 24th day of hospitalization, which confirmed the giant emphysema. The patient remains on long-term oxygen therapy. CONCLUSION: The COVID-19 has polymorphic manifestations, pneumonia is the most important one. There are relatively few reports associating COVID-19 and emphysema; furthermore, reports associating COVID-19 and giant emphysema are extremely scarce. CT scans can confirm the diagnosis and differentiate it from a pneumothorax. The pulmonary prognosis of the association of COVID-19 in its severe or critical form with giant emphysema remains poor.
Assuntos
COVID-19 , Enfisema Mediastínico , Enfisema Subcutâneo , Adulto , Humanos , Masculino , Pandemias , SARS-CoV-2RESUMO
In contrast to the significant advances in our understanding of the mesenchymal stem cell (MSC) populations in bone marrow (BM), little is known about the MSCs that are resident in the synovial joint and their possible roles in the tissue homeostasis, chronic inflammation as well as in repair. Neural crest is a transient embryonic structure, generating multipotential MSC capable of migrating along peripheral nerves and blood vessels to colonize most tissue types. In adult, these MSC can provide functional stromal support as a stem cell niche for lymphocyte progenitors for instance in the BM and the thymus. Critically, MSC have major immunoregulatory activities to control adverse inflammation and infection. These MSC will remain associated to vessels (perivascular (p) MSC) and their unique expression of markers such as myelin P0 and transcription factors (e.g. Gli1 and FoxD1) has been instrumental to develop transgenic mice to trace the fate of these cells in health and disease conditions. Intriguingly, recent investigations of chronic inflammatory diseases argue for an emerging role of pMSC in several pathological processes. In response to tissue injuries and with the release of host cell debris (e.g. alarmins), pMSC can detach from vessels and proliferate to give rise to either lipofibroblasts, osteoblasts involved in the ossification of arteries and myofibroblasts contributing to fibrosis. This review will discuss currently available data that suggest a role of pMSC in tissue homeostasis and pathogenesis of the synovial tissue and joints. Graphical abstract.
Assuntos
Artropatias/metabolismo , Células-Tronco Mesenquimais/metabolismo , Líquido Sinovial/metabolismo , Membrana Sinovial/metabolismo , Animais , Humanos , Inflamação/imunologia , Inflamação/metabolismo , Artropatias/imunologia , Células-Tronco Mesenquimais/imunologia , Crista Neural/imunologia , Crista Neural/metabolismo , Líquido Sinovial/imunologia , Membrana Sinovial/imunologiaRESUMO
OBJECTIVE: To scope and summarise available literature on the outcomes of pregnancy and associated factors in sub-Saharan African women with SLE. METHODS: Electronic databases and reference lists of retrieved articles were searched to identify relevant studies published from 1 January 2000 to 28 October 2019. Data were combined through narrative synthesis. RESULTS: We included four studies retrospectively reporting a total of 137 pregnancies in 102 women over a 26-year period. Mean age at conception ranged from 27.2 to 39.9 years. Kidney damage, the predominant organ manifestation before conception, was reported in 43 (42.2%) patients. Ninety-seven (70.8%) pregnancies resulted in 98 live births. SLE flares occurred in 44 (32.2%) pregnancies, mainly skin (20.4%) and renal (18.2%) flares. Major adverse pregnancy outcomes (APOs) were preterm birth 38.8%, low birth weight 29.8%, pregnancy loss 29.2% and pre-eclampsia 24.8%. The main factors associated with APOs were nephritis and SLE flares. CONCLUSION: Over two-thirds of pregnancies resulted in live birth in this cohort of sub-Saharan African women with SLE. The main APOs and associated factors described in other parts of the world are also seen in this region, but with high rates of APOs. A large prospective multinational study is warranted for more compelling evidence.
Assuntos
Lúpus Eritematoso Sistêmico/complicações , Nefrite Lúpica/complicações , Resultado da Gravidez/epidemiologia , Aborto Espontâneo/epidemiologia , Adulto , África Subsaariana/epidemiologia , Gerenciamento de Dados , Feminino , Humanos , Recém-Nascido de Baixo Peso , Nascido Vivo/epidemiologia , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Nefrite Lúpica/epidemiologia , Pré-Eclâmpsia/epidemiologia , Gravidez , Nascimento Prematuro/epidemiologia , Estudos RetrospectivosRESUMO
BACKGROUND: So far, only one meta-analysis has estimated the prevalence of rheumatoid arthritis (RA) in Africa. Out of 10 studies included in that meta-analysis, nine came from sub-Saharan African countries and had been published between 1968 and 1988. We will conduct a new systematic review and meta-analysis to update their estimates and provide more consistent prevalence data on RA in sub-Saharan Africa. METHODS: We will comprehensively search electronic databases to select observational studies addressing RA in sub-Saharan Africa and published as from 1 January 2000: PubMed, EMBASE, African Journals Online, Web of Science, and Global Index Medicus. Summary estimates will be derived through random-effects meta-analysis whenever possible. Alternatively, estimates will be reported through narrative synthesis when the random-effects meta-analysis will be impossible. The risk of bias will be assessed using standard methods. DISCUSSION: This systematic review and meta-analysis shall quantify the magnitude of RA morbidity and mortality in sub-Saharan Africa. Results from this review will be disseminated in peer-reviewed journals, conferences and on social media platforms. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020153483.
Assuntos
Artrite Reumatoide , África Subsaariana/epidemiologia , Artrite Reumatoide/epidemiologia , Humanos , Metanálise como Assunto , Prevalência , Revisões Sistemáticas como AssuntoRESUMO
Methotrexate (MTX) is the first line drug for the treatment of a number of rheumatic and non-rheumatic disorders. It is currently used as an anchor disease, modifying anti-rheumatic drug in the treatment of rheumatoid arthritis (RA). Despite the development of numerous new targeted therapies, MTX remains the backbone of RA therapy due to its potent efficacy and tolerability. There has been also a growing interest in the use of MTX in the treatment of chronic viral mediated arthritis. Many viruses-including old world alphaviruses, Parvovirus B19, hepatitis B/C virus, and human immunodeficiency virus-have been associated with arthritogenic diseases and reminiscent of RA. MTX may provide benefits although with the potential risk of attenuating patients' immune surveillance capacities. In this review, we describe the emerging mechanisms of action of MTX as an anti-inflammatory drug and complementing its well-established immunomodulatory activity. The mechanisms involve adenosine signaling modulation, alteration of cytokine networks, generation of reactive oxygen species and HMGB1 alarmin suppression. We also provide a comprehensive understanding of the mechanisms of MTX toxic effects. Lastly, we discussed the efficacy, as well as the safety, of MTX used in the management of viral-related rheumatic syndromes.
Assuntos
Antirreumáticos/farmacologia , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Metotrexato/farmacologia , Metotrexato/uso terapêutico , Adenosina , Alarminas , Anti-Inflamatórios/farmacologia , Artrite/tratamento farmacológico , Artrite/virologia , Citocinas/metabolismo , Ácido Fólico , Proteína HMGB1/efeitos dos fármacos , Humanos , Imunidade Inata , Inflamação , Metaloproteinases da Matriz/efeitos dos fármacos , Metotrexato/imunologia , NF-kappa B/efeitos dos fármacos , Poliaminas , Prostaglandinas , Espécies Reativas de OxigênioRESUMO
INTRODUCTION: To describe the epidemiology of joint pains and document analgesics usage in an African context. METHODS: Patients suffering from joint pain were recruited from nine sites located in Antananarivo, Madagascar, including 6 hospital services and 3 clinics. Doctors collected information on the etiology and characteristics of the patients' pain. Analgesics prescribed by these doctors were also documented. RESULTS: In total, 400 patients were enrolled in the study (52.5% women, mean age of 42.34 years ± 17.7 [4-86]). Pain of mechanical type was found in 260 participants, 65%; 95% CI [60.1% to 69.6%] and inflammatory type pains in 128 cases 32%; 95% CI [27.5% to 36.9%]. Mixed pains were found in 12 patients (3%). The median duration of pain prior to the consultation was 6.5 days. The average pain intensity was 57.9 ± 19.9 mm of a total of 100 mm maximum on a visual analogue scale, VAS. The etiologies of mechanical type pains were dominated by fracture, common low back pain and tendonitis. Arthrosis was the dominant cause of inflammatory type pain, followed by rheumatoid arthritis and gout. NSAIDs (74.5%) were the most frequently prescribed analgesics followed by paracetamol (49.5%), weak opioids (23%) and corticosteroids (12.25%). Two-thirds of medical prescriptions (65.3%) were of combined analgesics. CONCLUSION: These findings demonstrated that mechanical type pains were the main reason for consultations for joint pain in these situations in Antananarivo, Madagascar. The most frequently prescribed pain-relieving medications were NSAIDs, paracetamol, weak opioids and corticosteroids. This descriptive study may be a useful starting point for further epidemiological studies of pain in the African context.
Assuntos
Analgésicos/uso terapêutico , Artralgia/epidemiologia , Acetaminofen/uso terapêutico , Adolescente , Corticosteroides/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos Opioides/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Artralgia/tratamento farmacológico , Artralgia/etiologia , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Madagáscar/epidemiologia , Masculino , Pessoa de Meia-Idade , Medição da Dor , Adulto JovemRESUMO
Introduction : Avec l'ouverture récente du seul service du Rhumatologie à Madagascar en 2005, nous avons étudié l'évolution de la prise en charge des patients afin d'identifier les stratégies d'amélioration des services rendus aux patients dans les années à venir.Méthodologie : C'est une étude rétrospective descriptive sur analyse de dossiers de patients vus à l'unité de Rhumatologie du CHU Antananarivo entre janvier 2006 et 2011.Résultats : Nous avons retenu 1581 cas dont 1480 (94%) vus en consultation. Il y avait 111 nouveaux cas entre 2006-2007 contre 1062 entre 2010-2011. Le nombre des patients venant des îles voisines allait de 6 à 127 durant le même intervalle. La goutte et le rhumatisme articulaire aigu étaient les diagnostics les plus évoqués en ambulatoire, respectivement chez 76 et 74 patients. Seuls 26% de ces diagnostics étaient retenus dans notre service où les pathologies dégénératives dominaient (61%). Les rhumatismes inflammatoires représentaient 13% des cas. La quasi-totalité de ces patients recevaient une corticothérapie au long cours et les possibilités thérapeutiques sont restés les mêmes en cinq ans, avec un usage fréquent du Méthotrexate. Seuls 5,81% de ces patients bénéficiaient d'un traitement anti-ostéoporotique. La proportion de patients perdus de vue est importante, expliquée en partie par le nombre croissant de patients, non proportionnel à l'évolution de l'effectif des rhumatologues.Conclusion : Nos défis dans les 5 ans à venir sont de former plus de spécialistes, d'intensifier les activités de formation médicale continue et de trouver des moyens d'éducation thérapeutique efficients afin de maintenir les patients dans le circuit de soins